A 28-year-old woman with chronic hepatitis B (HBsAg positive for 5 years, HBeAg negative, anti-HBe positive, HBV DNA 50,000 IU/mL, elevated ALT) is being evaluated for antiviral therapy. According to standard guidelines, which criterion is an indication for initiating antiviral treatment in HBeAg-negative chronic hepatitis B?
- A HBsAg positivity for more than 1 year regardless of ALT or HBV DNA level
- B HBV DNA greater than 2000 IU/mL plus moderate-to-severe necroinflammation on liver biopsy ✓
- C Any detectable HBV DNA in serum regardless of ALT level
- D Elevated ALT alone without any HBV DNA testing
Explanation
For HBeAg-negative chronic hepatitis A, treatment is indicated when HBV DNA is greater than 2000 IU/mL plus either elevated ALT or moderate-to-severe necroinflammation/fibrosis on biopsy (AASLD and EASL guidelines). This patient meets both criteria (HBV DNA 50,000 IU/mL, elevated ALT). HBsAg positivity alone is not a treatment indication. Detectable HBV DNA without ALT elevation or histologic disease suggests the immune-tolerant or inactive carrier state and is not an indication. Elevated ALT alone without viral load assessment is insufficient for treatment decisions.
Reference: Harrison's Principles of Internal Medicine, 21st ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.